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ABSTRACT: Background: Diagnosis of Parkinson’s
disease (PD) is typically preceded by nonspeciﬁc presen-
tations in primary care.
Objectives: The objective of this study was to develop
and validate a prediction model for diagnosis of PD
based on presentations in primary care.
Setting: The settings were general practices providing
data for The Health Improvement Network UK primary
care database.
Methods: Data from 8,166 patients aged older than age
50 years with incident diagnosis of PD and 46,755 controls
were analyzed. Likelihood ratios, sensitivity, speciﬁcity, and
positive and negative predictive values for individual symp-
toms and combinations of presentations were calculated.
An algorithm for risk of diagnosis of PD within 5 years was
calculated using multivariate logistic regression analysis.
Split sample analysis was used for model validation with a
70% development sample and a 30% validation sample.
Results: Presentations independently and signiﬁcantly
associated with later diagnosis of PD in multivariate
analysis were tremor, constipation, depression or anxiety,
fatigue, dizziness, urinary dysfunction, balance problems,
memory problems and cognitive decline, hypotension,
rigidity, and hypersalivation. The discrimination and calibra-
tion of the risk algorithm were good with an area under the
curve of 0.80 (95% conﬁdence interval 0.78-0.81). At a
threshold of 5%, 37% of those classiﬁed as high risk would
be diagnosed with PD within 5 years and 99% of those
who were not classiﬁed as high risk would not be diag-
nosed with PD.
Conclusion: This risk algorithm applied to routine
primary care presentations can identify individuals at
increased risk of diagnosis of PD within 5 years to allow
for monitoring and earlier diagnosis of PD. © 2019 The
Authors. Movement Disorders published by Wiley Period-
icals, Inc. on behalf of International Parkinson and Move-
ment Disorder Society.
Key Words: algorithm; diagnosis; Parkinson’s disease;
prodromal; risk; risk calculator
A diagnosis of Parkinson’s disease (PD) is made when
classical features of slowness combined with other fea-
tures such as rigidity, tremor, and postural instability
are present.1 However, clinical symptoms leading to
presentation in primary care typically occur several years
before a diagnosis is made.2-8 These presentations pro-
vide an opportunity to identify those at increased risk of
diagnosis of PD, allowing for earlier diagnosis with more
effective treatment to improve quality of life9 as well as
enrollment into clinical trials with potential neuroprotec-
tive medications. A number of approaches using individ-
ual or combined risk and prediagnostic features to
identify higher risk individuals have been proposed, but
these are limited by availability of resources (eg, investi-
gations such as transcranial sonography) or rarity of the
risk or prediagnostic feature (eg, presence of rapid eye
movement sleep behavior disorder or genetic risk fac-
tors).10,11 In addition, all of these approaches require
active screening for risk and prediagnostic features. The
Movement Disorders Society Research criteria for pro-
dromal PD combine the published likelihood ratios of
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readily available risk and presenting factors and of more
speciﬁc investigations such as dopamine transporter
(DAT) imaging.12 However, these were derived from
multiple individual studies and are designed for active
screening of populations; predictive tools to identify
those in the prodromal phase of PD from primary care
presentations are lacking. We here report the develop-
ment of a risk model to (1) identify patients with possi-
ble prediagnostic PD for participation in future research
and (2) aid in the earlier recognition of PD as a cause for
symptoms patients present with in primary care.
Methods
Study Design and Data Source
We used data from a previous case-control study
identifying prediagnostic features of PD that occurred
signiﬁcantly more often in patients with a later diagno-
sis of PD than in matched controls.3 In brief, data were
derived from a large primary care database in the
United Kingdom, The Health Improvement Network,
which holds pseudanonymized longitudinal medical
records for more than 11 million individuals registered
with more than 500 general practices in the United
Kingdom. Information on symptoms, diagnoses, inter-
ventions, and referrals to secondary care are electroni-
cally recorded as read codes, a hierarchical coding
system used in U.K. primary care, which map on to
International Classiﬁcation of Diseases, 10th Revision
codes.13 The Health Improvement Network data are
representative of the U.K. general practice population
in terms of demographics and frequency and type of
consultations requested by patients, and electronically
coded diagnoses have been shown to be accurate.14 The
Health Improvement Network data collection scheme
was approved by UK South East National Health Ser-
vice multicenter research ethics committee, and the sci-
entiﬁc review committee approved the present study.
Study Population
We identiﬁed all individuals who had a read code
diagnosis of PD and at least 2 antiparkinsonian drug
prescriptions. A similar method for the identiﬁcation of
people with PD has been validated in another large pri-
mary care database in the United Kingdom.15 Diagnos-
tic read codes for PD were identiﬁed using published
methods (Appendix).16 The earliest date of Read code
diagnosis or antiparkinsonian drug prescription was
taken as the index date. Individuals with a diagnosis of
PD before the age of 50 years were excluded, as were
those with secondary parkinsonism, dementia before
PD diagnosis, drug-induced parkinsonism, or schizo-
phrenia (because these individuals are likely to have
had substantial exposure to dopamine antagonist
drugs). Six times as many controls as cases with similar
distribution of age, gender, and registration period at
the date of a general practice consultation (index date)
were randomly selected (frequency matching) using a
random sampling routine. Individuals were included
only if they had at least 1 year of data before the index
date. This inclusion criterion ensured that individuals
had at least 1 year between registration with the GP
practice and diagnosis of PD, which limits the possibil-
ity of inclusion of patients with PD diagnosed previ-
ously but ﬁrst recorded by the new GP during the
patient registration period.17
Data Extraction
Symptoms initially included in the analysis were ﬁrst
presentations of late-onset (>50 years of age) anxiety
and depression, fatigue, apathy, insomnia, balance
impairment, dizziness, hypotension, anosmia, hypersali-
vation, constipation, urinary dysfunction, erectile dys-
function, memory problems, neck pain or stiffness,
shoulder pain or stiffness, rigidity, tremor, and cognitive
decline. All symptoms were deﬁned using read code
lists.16 In addition, we used prescriptions for anxiolytics,
antidepressants, drugs for constipation, and hypnotics
and drugs for erectile dysfunction to identify symptoms
of anxiety, depression, constipation, insomnia, and erec-
tile dysfunction, respectively. For the variables anxiety
and depression with onset >50 years of age, those with a
record of anxiety or depression before age 50 years were
treated as missing. As symptoms coded shortly after reg-
istration with the GP potentially represent prevalent and
not new health issues, the exclusion period was 1 year
after GP registration for anxiety or depression and
6 months for all other symptoms.
Analysis
We restricted analysis to the ﬁrst presentations within
5 years of diagnosis of PD or index date in controls.
We calculated the percentage of patients with each pre-
sentation in patients and controls. To allow for com-
parison with previously published data on risk
associated with the examined prodromal features,12 we
also calculated sensitivity, speciﬁcity, positive and nega-
tive likelihood ratios, positive predictive values (PPVs)
and negative predictive values for each presentation,
and smoking (current, exsmoker, or never) and alcohol
consumption (current, former, or never). PPVs were cal-
culated using Bayes’ theorem,18 where posterior odds
of disease = prior odds × likelihood ratio. For prior
odds, we used a prevalence rate of PD for older than
the age of 50 years of 1,400 per 100,000.19 In addition,
we calculated PPV for all 2-symptom combinations of
2 individually signiﬁcant symptom presentations.
Univariate logistic regression was used to examine
the differences between cases and controls in each pre-
diagnostic presentation as well as in smoking status
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and alcohol consumption (as they are known to have
negative association with risk of PD), adjusted for age
group, gender, and index date.
Development of the Risk Model
We then separated the dataset into a development and
a validation sample using random sampling of individ-
uals, comprising 70% and 30% of the original dataset,
respectively. Using the development sample, symptoms
independently associated with PD diagnosis with a
P value < .1 were entered into a backward multivariate
logistic regression analysis with PD diagnosis as the
dependent variable with a P removal = .05. We com-
bined the variables anxiety and depression with onset
>50 years (present if either for the ﬁrst time occurred
after the age of 50 years) because these symptoms are
often comorbid12 and therefore not independent. We
then applied the ﬁnal model to the validation sample
and compared the performance in the development and
validation samples. As this study is a case-control study,
the estimated intercept is too high and leads to an over-
estimate of the actual risk of PD in the population.
Therefore, corrected intercepts were calculated for each
age group/gender combination (see Box 1) so that the
average risk predicted by the model reﬂects the age- and
gender-speciﬁc prevalence of PD20 (Table S3). The dis-
criminatory ability of the ﬁnal model was quantiﬁed
through an area under a receiver operating characteristic
curve with sensitivity and speciﬁcity.21 Calibration was
assessed by graphically comparing the observed and pre-
dicted values within decile groups of predicted risk. (The
same values used for the Hosmer-Lemeshow test; the
P value is not reported because this test tends to produce
signiﬁcant results in large samples, even when the
observed and predicted values are very close.22) The
model’s calibration was also assessed using the calibra-
tion slope.23 All analyses were performed using Stata
(version 14; StataCorp, College Station, Texas).
Results
A total of 8,166 individuals with PD and 46,755 con-
trols were included in the study (Table 1).3 Figure 1 shows
the frequency of the potential prediagnostic features in the
PD group when compared with the control group within
5 years before diagnosis. The most common prediagnostic
symptom of PD within 5 years before diagnosis was
tremor, with 41% of individuals reporting symptoms to
their GP compared with less than 1% of controls. Consti-
pation occurred in 37% versus 23% in controls, depres-
sion in 18% versus 10%, fatigue in 15% versus 8%,
dizziness in 14% versus 9%, anxiety in 12% versus 7%,
and shoulder stiffness or pain in 12% versus 9%. In uni-
variate logistic regression, all presentations except apathy
and neck pain/stiffness had a signiﬁcant association with
PD diagnosis at a signiﬁcance level of P < .05 (Supporting
Information Table S1). Sensitivity, speciﬁcity, positive and
negative likelihood ratios, and positive and negative pre-
dictive values of each individual presentation are given in
Supporting Information Table S2.
Development of the Model
In the development sample following multivariate
analysis, the following presentations remained signiﬁcant
predictors of diagnosis of PD: tremor, hypersalivation,
rigidity, memory problems, urinary dysfunction, fatigue,
hypotension, dizziness, constipation, cognitive decline,
balance problems, depression and/or anxiety, and smok-
ing status (Table 2). Insomnia, anosmia, and shoulder
pain were no longer signiﬁcantly associated with later
diagnosis of PD in the multivariate analysis. For the
model construction, Supporting Information Table S3
shows the factors to be subtracted in the risk model to
adjust for patient age and gender. In the ﬁnal model the
area under the curve (AUC) was 0.80 (95% conﬁdence
interval [CI] 0.78-0.81; Fig. 2). Validation of the model
in the validation sample showed a similar AUC of 0.80
(95%CI 0.78-0.81; P = .69). The calibration slope was
BOX 1.
The risk model constructed to calculate predicted
risk of PD is the following:
Patient’s risk of PD=
1
1 + exp −patient0s risk scoreð Þ ;
where Patient
0
s risk score = b1×I(Tremor)+ b2×I
(Constipation) + b3×I(Depression and/or Anxiety) +
b4×I(Fatigue) + b5×I(Dizziness) + b6×I(Urinary Dys-
function) + b7×I(Balance Problems) + b8×I(Memory
Problems) + b9×I(Hypotension) + b10×I(Rigidity) +
b11×I(Cognitive Decline) + b12×I(Hypersalivation) +
b13×I(Exsmoker) + b14×I(Current Smoker) + b15×I
(age = 50 and male) + b16×I(age = 60 and male) +
b17×I(age = 70 and male) + b18×I(age = 80 and
male) + b19×I(age = 90 and male) + b20×I(age = 50
and female)+ b21×I(age = 60 and female) + b22×I
(age = 70 and female) + b23×I(age = 80 and female) +
b24×I(age = 90 and female)
Using an example for the ﬁnal model, a 70-year-
old male who has constipation, tremor, depression,
anxiety, and urinary dysfunction has a predicted
risk of Parkinson’s disease of 67% (61%-72%).
Based on Tables 2 and Supporting Information
Table S3, the patient’s risk score = 0.50 + 4.58 + 0.43 +
0.52-5.32 = 0.71.
The patient’s risk of PD = 1/(1 + exp(−0.71)) = 0.67
or 67%.
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close to 1 in the validation sample, suggesting good cali-
bration (Supporting Information Figure S1).
As tremor had a very high predictive value, we also
repeated the analysis without the inclusion of tremor
(Supporting information Tables 4 and 5 and Figures 2
and 3). This showed similar results for the other variables,
albeit with a lower AUC of 0.66 (95%CI 0.65-0.67).
Risk Classiﬁcation
Using a range of possible cut-offs to indicate high risk
for PD, the speciﬁcity of the risk algorithm was high and
there was a high negative predictive value, but lower
sensitivity and PPV (Tables 3 and 4). For example, if
we chose a threshold of 5% to split the patients into
high-risk and low-risk groups based on their predicted
risk, the speciﬁcity was 98.94%, negative predictive
value was 99.20%, sensitivity was 43.48%, and PPV
was 36.88%.
Discussion
We used routinely collected primary care data to
develop a risk model for diagnosis of PD within 5 years
following the ﬁrst presentation with possible prediag-
nostic features. It provides a clinical tool for use in pri-
mary care, which does not require additional testing
but allows one to identify individuals older than
50 years for monitoring or early referral for suspected
diagnosis of PD. It therefore has the potential to allow
for earlier diagnosis of PD, which is typically delayed
by >1 year,24 leading to delayed treatment and reduced
quality of life9 and to refer and initiate treatment early
and effectively. In addition, it provides the opportunity
to identify individuals in the general population for
studies of the prodromal phase of PD, which so far
have required the identiﬁcation of rare factors associ-
ated with high risk (eg, gene carriers of leucine-rich
repeat kinase 2 [LRRK2] mutations), expensive investi-
gations, or active screening of large volunteer cohorts.
As this tool does not require any additional investiga-
tions other than information already collected in rou-
tine health care records and as it is based in primary
care, it provides researchers with a method to identify
individuals with increased risk on a large scale and
from a representative general population. Although fur-
ther examination, monitoring, or testing is likely to be
TABLE 1. Characteristics of patients with Parkinson’s
disease and controls
Characteristic
Parkinson’s disease,
n = 8,166
Controls,
n = 46,755
Gender, n (%)
Men 4,859 (59.5) 27,684 (59.21)
Women 3,307 (40.5) 19,071 (40.79)
Age at index date,
10-year age bands, n (%)
50-60 649 (7.95) 3,740 (8.00)
60-70 1,855 (22.72) 10,986 (23.50)
70-80 3,437 (42.09) 20,324 (43.47)
80-90 2,039 (24.97) 11,113 (23.77)
90+ 186 (2.28) 892 (1.72)
Years of follow-up, mean (SD) 4.1 (1.27) 4.0 (1.33)
Smoking status, n (%)
Never 4,396 (53.83) 20,589 (44.04)
Past 2,076 (25.42) 12,196 (26.08)
Present 711 (8.71) 7,594 (16.24)
Data missing 983 (12.04) 6,376 (13.64)
Alcohol consumption, n (%)
Never 1,042 (12.76) 5,751 (12.30)
Past 371 (4.54) 1,743 (3.73)
Present 5,240 (64.17) 29,217 (62.49)
Data missing 1,513 (18.53) 10,044 (21.48)
FIG. 1. Percentage of individual symptom presentations in controls and PD patients.
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necessary for inclusion in further biomarker or treat-
ment trials (eg, neurological examination, imaging, or
genetic testing), this approach overcomes some of the
challenges in this ﬁeld, including the ethical dilemma of
identifying individuals at risk who do not have trouble-
some symptoms requiring treatment, as individuals are
considered at a time when they are seeking medical help
for their symptoms.
Our results for individual prediagnostic features are
comparable to those that were also included in the
recently published Movement Disorders Society research
criteria for prodromal PD,12 although the predictive fac-
tors we included differed because of the nature of the
studies (eg, the Movement Disorders Society criteria
included investigational results and the present data
include a wider range of clinical features). These criteria
are the current standard for classiﬁcation of risk of PD
as they were based on an evidence based systematic
review of risk reported in the literature. However, the
classiﬁcation is necessarily limited by the pooling of dif-
ferent studies and does not account for possible cooccur-
rence of symptoms, for example, constipation and
urinary symptoms. The current study used a single large
population to derive likelihood ratios, which were
adjusted for each other in multiple regression analysis,
thus reducing this limitation. It also uses solely clinical
features that are easily attainable in routine clinical set-
tings. Nalls and colleagues11 also used a multivariate
regression analysis approach to develop a risk model for
diagnosis of PD in already established cases and
included a genetic risk score. Apart from the genetic
score, the University of Pennsylvania Smell Identiﬁcation
FIG. 2. Receiver operating characteristic curves for the prediction of PD for the model with all statistically signiﬁcant prediagnostic symptom presenta-
tions of PD, smoking status, gender, and age group in the development and validation datasets.
TABLE 2. Multivariable logistic regression analysis for association of symptom presentations and risk factors with diagnosis
of Parkinson’s disease, adjusted for age group and gender in the development sample
Presentation/Risk factor Regression coefﬁcient P value 95% CI OR 95% CI
Intercept −2.47 <.001 −2.54 to −2.41
Tremor 4.58 <.001 4.41 to 4.74 97.21 82.55 to 114.49
Constipation 0.50 <.001 0.41 to 0.58 1.64 1.51 to 1.79
Depression and/or anxiety 0.43 <.001 0.32 to 0.53 1.53 1.38 to 1.69
Fatigue 0.38 <.001 0.25 to 0.51 1.46 1.28 to 1.67
Dizziness 0.15 .025 0.02 to 0.29 1.17 1.02 to 1.33
Urinary dysfunction 0.52 <.001 0.34 to 0.70 1.68 1.40 to 2.00
Balance problems 1.39 <.001 1.17 to 1.62 4.03 3.22 to 5.04
Memory problems 0.34 .018 0.06 to 0.63 1.41 1.06 to 1.87
Hypotension 0.46 .001 0.18 to 0.74 1.58 1.19 to 2.10
Rigidity 2.49 <.001 2.11 to 2.88 12.10 8.22 to 17.83
Cognitive decline 1.00 .001 0.39 to 1.61 2.72 1.48 to 5.01
Hypersalivation 1.99 <.001 1.08 to 2.91 7.35 2.95 to 18.28
Smoking status
Never 0 <.001 1
Past −0.33 −0.42 to −0.24 0.72 0.66 to 0.78
Present −0.86 −0.98 to −0.73 0.42 0.37 to 0.48
95% CI, 95% conﬁdence interval.
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Test (UPSIT) together with age, gender, and family his-
tory, independently contributed to prediction of PD in
established disease, with an AUC of 0.60 (95% CI
0.56-0.65) for demographic features, 0.64 (95% CI
0.59-0.69) for the genetic risk score, 0.90 (95%
CI 0.87-0.93) for the UPSIT score, and 0.92 (95% CI
0.90-0.95) for the integrated score. In our study of pre-
diagnostic PD, using primary care presentations (with-
out UPSIT scores or genetic testing and not including
family history), we were still able to achieve an AUC of
0.80 (95% CI 0.78-0.81), suggesting that the clinical
features are a very effective tool to screen for risk of
future PD and that further reﬁnement through addi-
tional tests, such as UPSIT or genetic testing, may
achieve even higher predictive accuracy. Several studies
are currently underway to identify further biomarkers
and tools to identify risk of PD for clinical trials, includ-
ing the Parkinson associated risk syndrome (PARS)
study, which has already established that screening with
UPSIT is an effective way to stratify for those with
makers of PD and those without.25,26 The Tübinger
Evaluation of Risk Factors for Early Detection of Neu-
rodegeneration (TREND) study established transcranial
sonography as a useful screening tool,27 and the
PREDICT-PD study has pioneered an internet-based
assessment tool.28 Incorporating the current risk model
as a ﬁrst step into these studies is likely to improve their
ability to screen from populations in primary care and
the general population and select individuals for inclu-
sion into trials. The timeframe of 5 years is longer than
the duration of most traditional treatment trials but
allows for further enrichment using targeted testing.
It is noteworthy that tremor was the clinical feature
with the highest predictive value. This may suggest that
some patients may already have diagnosable PD, but
even in specialist settings making a diagnosis of PD
based on presence of tremor alone (even if typical of
PD), is currently not possible according to diagnostic
criteria. Although the study was not designed to distin-
guish those with tremor as a result of early PD from
those with tremor as a result of other causes, the tool
allows for the incorporation of tremor in the risk pre-
diction algorithm. The algorithm, however, does not
require the presence of tremor and even when excluding
tremor the algorithm based on the combination of
other risk and diagnostic features provided acceptable
predictive accuracy (AUC 0.66).
Study Limitations
This study is likely to have underestimated the inci-
dence of prediagnostic features of PD in patients and
controls, as only presentations recorded in health care
records by primary care physicians were included rather
than all symptoms that may have been present on active
screening. In addition, these symptom codes are not
strict diagnostic codes but reﬂect presenting complaints
or ﬁndings. However, these data are likely to be clini-
cally relevant as only symptoms present when patients
sought medical help were included, and the risk of
recall bias is low as the information was collected from
prospectively collected primary care data. This dataset
therefore provides prospective information for clinically
important features in primary care, making it a more
clinically relevant dataset. Despite this potential under-
estimation of its true predictive power of the risk score
we found that the risk score had good predictive power
with an AUC of 0.80, making this a useful tool to iden-
tify for those who may beneﬁt from further assessment,
and the predictive power is likely to be even higher in
prospective active screening programs. This tool may
help clinicians to identify those whom they should
review carefully for features of PD.
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TABLE 3. Risk classiﬁcation using the Parkinson’s disease
risk algorithm for all factors in the ﬁnal model
Cut off
for high
risk, %
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95%CI)
NPV
(95%CI)
1 55.86
(54.63-57.07)
91.98
(91.70-92.26)
9.00
(8.67-9.35)
99.32
(99.30-99.34)
5 43.48
(42.26-44.70)
98.94
(98.83-99.05)
36.88
(34.50-39.33)
99.20
(99.18-99.21)
10 40.84
(39.63-42.05)
99.18
(99.08-99.27)
41.48
(38.66-44.36)
99.16
(99.14-99.18)
20 32.41
(31.27-33.57)
99.36
(99.27-99.44)
41.81
(38.61-45.08)
99.04
(99.03-99.05)
95% CI, 95% conﬁdence interval; NPV, negative predictive values; PPV,
positive predictive values.
TABLE 4. Risk classiﬁcation using the Parkinson’s disease
risk algorithm for all factors in the ﬁnal model (without
tremor)
Cut off
for high
risk, %
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
PPV
(95%CI)
NPV
(95%CI)
1 47.51
(46.28-48.74)
71.03
(70.55-71.49)
2.28
(2.21-2.34)
98.96
(98.94-98.99)
5 4.56
(4.07-5.10)
99.35
(99.26-99.43)
9.08
(7.77-10.58)
98.65
(98.647-98.66)
10 1.99
(1.66-2.36)
99.83
(99.78-99.87)
13.90
(10.68-17.90)
98.625
(98.62-98.63)
95% CI, 95% conﬁdence interval; NPV, negative predictive values; PPV,
positive predictive values.
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